Top

Published in:

01-06-2014 | Research Article

Differences in Transport Mechanisms of trans-1-Amino-3-[¹⁸F]Fluorocyclobutanecarboxylic Acid in Inflammation, Prostate Cancer, and Glioma Cells: Comparison with l-[Methyl-¹¹C]Methionine and 2-Deoxy-2-[¹⁸F]Fluoro-d-Glucose

Authors: Shuntaro Oka, Hiroyuki Okudaira, Masahiro Ono, David M. Schuster, Mark M. Goodman, Keiichi Kawai, Yoshifumi Shirakami

Published in: Molecular Imaging and Biology | Issue 3/2014

Abstract

Purpose

We aimed to elucidate trans-1-amino-3-[¹⁸F]fluorocyclobutanecarboxylic acid (anti-[¹⁸F]FACBC) uptake mechanisms in inflammatory and tumor cells, in comparison with those of l-[methyl-¹¹C]methionine ([¹¹C]Met) and 2-deoxy-2-[¹⁸F]fluoro-d-glucose ([¹⁸F]FDG).

Procedures

Using carbon-14-labeled tracers, in vitro time-course, pH dependence, and competitive inhibition uptake experiments were performed in rat inflammatory (T cells, B cells, granulocytes, macrophages), prostate cancer (MLLB2), and glioma (C6) cells.

Results

Anti-[¹⁴C]FACBC uptake ratios of T/B cells to tumor cells were comparable, while those of granulocytes/macrophages to tumor cells were lower than those for [¹⁴C]FDG. Over half of anti-[¹⁴C]FACBC uptake by T/B and tumor cells was mediated by Na⁺-dependent amino acid transporters (system ASC), whereas most [¹⁴C]Met transport in all cells was mediated by Na⁺-independent carriers (system L).

Conclusions

The low anti-[¹⁸F]FACBC accumulation in granulocytes/macrophages may be advantageous in discriminating inflamed regions from tumors. The significant anti-[¹⁸F]FACBC uptake in T/B cells may cause false-positives in some cancer patients who undergo FACBC-positron emission tomography (PET).

Available only for authorised users

Fanti S, Franchi R, Battista G et al (2005) PET and PET-CT. State of the art and future prospects. Radiol Med 110:1–15PubMed

Singhal T, Narayanan TK, Jain V et al (2008) ¹¹C-l-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol 10:1–18PubMedCrossRef

Shoup TM, Olson J, Hoffman JM et al (1999) Synthesis and evaluation of [¹⁸F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors. J Nucl Med 40:331–338PubMed

Akhurst T, Beattie B, Gogiberidze G, et al. (2006) [¹⁸F]FACBC imaging of recurrent gliomas: a comparison with [¹¹C]methionine and MRI [abstract]. J Nucl Med 47:79P.

Oka S, Hattori R, Kurosaki F et al (2007) A preliminary study of anti-1-amino-3-¹⁸F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer. J Nucl Med 48:46–55PubMed

Sasajima T, Ono T, Shimada N et al (2013) Trans-1-amino-3-¹⁸F-fluorocyclobutanecarboxylic acid (anti-¹⁸F-FACBC) is a feasible alternative to ¹¹C-methyl-l-methionine and magnetic resonance imaging for monitoring treatment response in gliomas. Nucl Med Biol 40:808–815PubMedCrossRef

Schuster DM, Taleghani PA, Nieh PT et al (2013) Characterization of primary prostate carcinoma by anti-1-amino-2-[¹⁸F] -fluorocyclobutane-1-carboxylic acid (anti-3-[¹⁸F] FACBC) uptake. Am J Nucl Med Mol Imaging 3:85–96PubMedCentralPubMed

Sfanos KS, De Marzo AM (2012) Prostate cancer and inflammation: the evidence. Histopathology 60:199–215PubMedCrossRef

Okudaira H, Shikano N, Nishii R et al (2011) Putative transport mechanism and intracellular fate of trans-1-amino-3-¹⁸F-fluorocyclobutanecarboxylic acid in human prostate cancer. J Nucl Med 52:822–829PubMedCrossRef

10.

Oka S, Okudaira H, Yoshida Y et al (2012) Transport mechanisms of trans-1-amino-3-fluoro[1-¹⁴C]cyclobutanecarboxylic acid in prostate cancer cells. Nucl Med Biol 39:109–119PubMedCrossRef

11.

Okudaira H, Nakanishi T, Oka S et al (2013) Kinetic analyses of trans-1-amino-3-[¹⁸F]fluorocyclobutanecarboxylic acid transport in Xenopus laevis oocytes expressing human ASCT2 and SNAT2. Nucl Med Biol 40:670–675PubMedCrossRef

12.

Hediger MA, Romero MF, Peng JB et al (2004) The ABCs of solute carriers: physiological, pathological and therapeutic implications of human membrane transport proteins. Pflugers Arch 447:465–468PubMedCrossRef

13.

Kanai Y, Fukasawa Y, Cha SH et al (2000) Transport properties of a system y⁺L neutral and basic AA transporter. Insights into the mechanisms of substrate recognition. J Biol Chem 275:20787–20793PubMedCrossRef

14.

Rau FC, Weber WA, Wester HJ et al (2002) O-(2-[¹⁸F]Fluoroethyl)-l-tyrosine (FET): a tracer for differentiation of tumour from inflammation in murine lymph nodes. Eur J Nucl Med Mol Imaging 29:1039–1046PubMedCrossRef

15.

Tsukada H, Sato K, Fukumoto D et al (2006) Evaluation of d-isomers of O-¹¹C-methyl tyrosine and O-¹⁸F-fluoromethyl tyrosine as tumor-imaging agents in tumor-bearing mice: comparison with l- and d-¹¹C-methionine. J Nucl Med 47:679–688PubMed

16.

Tsuyuguchi N, Sunada I, Ohata K et al (2003) Evaluation of treatment effects in brain abscess with positron emission tomography: comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine. Ann Nucl Med 17:47–51PubMedCrossRef

17.

Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883–899PubMedCentralPubMedCrossRef

18.

Segel GB, Simon W, Lichtman MA (1984) Multicomponent analysis of amino acid transport in human lymphocytes. Diminished l-system transport in chronic leukemic B lymphocytes. J Clin Invest 74:17–24PubMedCentralPubMedCrossRef

19.

Ishii T, Sugita Y, Bannai S (1987) Regulation of glutathione levels in mouse spleen lymphocytes by transport of cysteine. J Cell Physiol 133:330–336PubMedCrossRef

20.

Gmünder H, Eck HP, Dröge W (1991) Low membrane transport activity for cystine in resting and mitogenically stimulated human lymphocyte preparations and human T cell clones. Eur J Biochem 201:113–117PubMedCrossRef

21.

Iruloh CG, D'Souza SW, Fergusson WD et al (2009) Amino acid transport systems beta and A in fetal T lymphocytes in intrauterine growth restriction and with tumor necrosis factor-alpha treatment. Pediatr Res 65:51–56PubMedCentralPubMedCrossRef

22.

Gaugitsch HW, Prieschl EE, Kalthoff F et al (1992) A novel transiently expressed, integral membrane protein linked to cell activation. Molecular cloning via the rapid degradation signal AUUUA. J Biol Chem 267:11267–11273PubMed

23.

Matsumoto Y, Satoh-Ueno K, Yoshimura A et al (1999) Identification and immunological characterization of a novel 40-kDa protein linked to CD98 antigen. Cell Struct Funct 24:217–226PubMedCrossRef

24.

Levring TB, Hansen AK, Nielsen BL et al (2012) Activated human CD4⁺ T cells express transporters for both cysteine and cystine. Sci Rep 2:266PubMedCentralPubMedCrossRef

25.

Fuchs BC, Bode BP (2005) Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol 15:254–266PubMedCrossRef

26.

Newsholme P (2001) Why is l-glutamine metabolism important to cells of the immune system in health, postinjury, surgery or infection? J Nutr 131:2515S–2522SPubMed

27.

Qu W, Oya S, Lieberman BP et al (2012) Preparation and characterization of l-[5-¹¹C]-glutamine for metabolic imaging of tumors. J Nucl Med 53:98–105PubMedCrossRef

28.

Ploessl K, Wang L, Lieberman BP et al (2012) Comparative evaluation of ¹⁸F-labeled glutamic acid and glutamine as tumor metabolic imaging agents. J Nucl Med 53:1616–1624PubMedCrossRef

29.

Shreve PD, Anzai Y, Wahl RL (1999) Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 19:61–77PubMedCrossRef

30.

Fossati G, Ricevuti G, Edwards SW et al (1999) Neutrophil infiltration into human gliomas. Acta Neuropathol 98:349–354PubMedCrossRef

31.

Kaim AH, Weber B, Kurrer MO et al (2002) Autoradiographic quantification of ¹⁸F-FDG uptake in experimental soft-tissue abscesses in rats. Radiology 223:446–451PubMedCrossRef

32.

Zhao S, Kuge Y, Kohanawa M et al (2008) Usefulness of ¹¹C-methionine for differentiating tumors from granulomas in experimental rat models: a comparison with ¹⁸F-FDG and ¹⁸F-FLT. J Nucl Med 49:135–141PubMedCrossRef

33.

Terakawa Y, Tsuyuguchi N, Iwai Y et al (2008) Diagnostic accuracy of ¹¹C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 49:694–699PubMedCrossRef

34.

Ohtsuki S, Uchida Y, Kubo Y, Terasaki T (2011) Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects. J Pharm Sci 100:3547–3559PubMedCrossRef

Title: Differences in Transport Mechanisms of trans-1-Amino-3-[18F]Fluorocyclobutanecarboxylic Acid in Inflammation, Prostate Cancer, and Glioma Cells: Comparison with l-[Methyl-11C]Methionine and 2-Deoxy-2-[18F]Fluoro-d-Glucose
Authors: Shuntaro Oka
Hiroyuki Okudaira
Masahiro Ono
David M. Schuster
Mark M. Goodman
Keiichi Kawai
Yoshifumi Shirakami
Publication date: 01-06-2014
Publisher: Springer US
Published in: Molecular Imaging and Biology / Issue 3/2014
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-013-0693-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Differences in Transport Mechanisms of trans-1-Amino-3-[¹⁸F]Fluorocyclobutanecarboxylic Acid in Inflammation, Prostate Cancer, and Glioma Cells: Comparison with l-[Methyl-¹¹C]Methionine and 2-Deoxy-2-[¹⁸F]Fluoro-d-Glucose

Abstract

Purpose

Procedures

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Procedures

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2014

Evaluation of Rho-Kinase Activity in Mice Brain Using N-[11C]Methyl-hydroxyfasudil with Positron Emission Tomography

Assessment of Global Cardiac Uptake of Radiolabeled Iron Oxide Nanoparticles in Apolipoprotein-E-Deficient Mice: Implications for Imaging Cardiovascular Inflammation

Spatial Vascular Volume Fraction Imaging for Quantitative Assessment of Angiogenesis

Validation of Fluorescence Molecular Tomography/Micro-CT Multimodal Imaging In Vivo in Rats

Imaging Tumour ATB0,+ Transport Activity by PET with the Cationic Amino Acid O-2((2-[18F]fluoroethyl)methyl-amino)ethyltyrosine

Examining Changes in [18 F]FDG and [18 F]FLT Uptake in U87-MG Glioma Xenografts as Early Response Biomarkers to Treatment with the Dual mTOR1/2 Inhibitor AZD8055